- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
-
P/E - Value Plays or Value Traps?
-
Generic Players Continue to Impress in H1
-
FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
-
Our Monthly Buy / Sell List
-
Cephalon Chugs Along, Despite Fentora, Provigil Setbacks
-
S&P 500: Ten Stocks to Watch
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
Nasdaq 100 Stocks Up An Average of 20% YTD
-
Top Ten S&P 500 Value Score Stocks
-
Wall Street Breakfast: Must-Know News
-
Cheap Stocks from the S&P 500
-
A Look at D.E. Shaw's Q408 Holdings: Just for Fun
-
First Convertible Bond ETF Comes to Market
-
FDA Calendar Updates: Santarus, Cephalon, AstraZeneca, Dendreon, Gilead, Novo Nordisk
-
Morphosys: A Biotech Rule Breaker (Part 2)
-
2 Potential Pharma M&A Targets: Cephalon and Genzyme
-
FDA and Clinical Trial Updates: United Therapeutics Faces Delays
-
Wall Street Breakfast: Must-Know News
-
Options Recap for Monday
-
Little Rays of Sunshine in the Markets
-
Bullish Thesis for Biotech Remains Intact
-
Which CEO Is the Best Wealth Creator?
-
Hedge Fund Portfolio Tracking: Citadel Investment Group (Ken Griffin), Q3 2008
-
2009: Positive Outlook for Biotech
-
Long/Short Hedge Strategy for Smaller Cap Stocks
-
New Index of Health Product Innovators
-
Trading on FDA Decisions: BioDelivery Sciences Could Have a Big '09
-
How Pharma Is Faring in the Financial Crisis
-
Health Innovator's Index: Does R&D Lead to Higher Stock Prices?
-
S&P 500 Index: Six More Changes
-
Recessionary Equity Strategies: Still Going for Growth
-
Biotech Update: Arena Pharmaceuticals, Acusphere, Cephalon, ViroPharma, Auxilium
-
SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial
-
Wall Street Breakfast: Must-Know News
-
Lowest P/E Ratios in the Nasdaq 100
-
Wall Street Breakfast: Must-Know News
-
Fast Money Recap, 4/9/08: Airlines MayTake Off
-
Cephalon’s New CLL Drug Should Please Patients and Investors
-
Pfizer Should Buy Amgen or Wyeth - Credit Suisse
-
Under The Radar News - Wednesday
-
Wall Street Breakfast: Must-Know News